尼洛替尼与伊马替尼一线治疗初发慢性髓性白血病患者的比较研究

OBJECTIVE: To compare the cytogenetic and molecular responses, outcomes and severe hematologic toxicity of nilotinib and imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase（CML-CP）. METHODS: Newly diagnosed CML-CP patients were consecutively recru...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2019
Materias:
论著
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342677/
https://www.ncbi.nlm.nih.gov/pubmed/32023729
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.12.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342677/
https://www.ncbi.nlm.nih.gov/pubmed/32023729
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2019.12.005

Ejemplares similares